{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:55:25Z","timestamp":1790837725082,"version":"4.1.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>While autoantibodies targeting extracellular antigens, such as those in myasthenia gravis, are established mediators of disease, autoantibodies recognizing intracellular antigens in inflammatory myopathies have traditionally been considered nonpathogenic. This review examines evidence challenging that paradigm and highlights recent advances in understanding the origins and pathogenic functions of autoantibodies in myositis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>In several forms of myositis, immunoglobulin accumulates within muscle fibers in a distribution mirroring that of the cognate autoantigen. Muscle biopsies demonstrate functional consequences consistent with disruption of the targeted autoantigen, as well as secondary muscle damage and inflammation. These effects are reproduced in vitro by forced autoantibody internalization. Local plasma cells may facilitate this process by releasing cytoplasmic contents into neighboring cells, including immunoglobulin RNA. In paraneoplastic dermatomyositis, genetic alterations of the targeted autoantigen are frequently identified in tumors, suggesting that immune responses to somatic tumor mutations may initiate autoantibody production. In immune checkpoint inhibitor\u2013associated myositis, autoantibodies may contribute to disease by acting as chemoattractants for drug-activated T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Recent findings support a direct pathogenic role for autoantibodies in several autoantibody-defined myositis subtypes and provide new insights into their origins and contribution to immune-mediated muscle injury, while also suggesting broader roles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001196","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:00:13Z","timestamp":1788336013000},"page":"448-455","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pathogenesis of autoantibodies in inflammatory myopathies"],"prefix":"10.1097","volume":"38","author":[{"given":"Katharine Ching","family":"Chung","sequence":"first","affiliation":[{"name":"Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianzi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago","family":"Pinal-Fernandez","sequence":"additional","affiliation":[{"name":"Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O\u2019Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"R2-20261001","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol"},{"key":"R3-20261001","author":"Pinal-Fernandez","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R5-20261001","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/ard-2023-223873","article-title":"Transcriptional derepression of CHD4\/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies","volume":"82","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"103962","DOI":"10.1016\/j.autrev.2025.103962","article-title":"Autoantibody internalization in myositis skeletal muscle: emerging evidence, mechanistic insights, and therapeutic relevance","volume":"25","author":"Kirou","year":"2026","journal-title":"Autoimmun Rev"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ard.2025.10.018","article-title":"Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis","volume":"85","author":"Moreno-C\u00e1rdenas","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1093\/rheumatology\/keab260","article-title":"TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1\u03b3 positive cancer-associated dermatomyositis","volume":"60","author":"Cordel","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"R11-20261001","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1*11:01 in antihydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2665-9913(23)00003-6","article-title":"Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial","volume":"5","author":"Mammen","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"R14-20261001","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/271067a0","article-title":"Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors","volume":"271","author":"Alarcon-Segovia","year":"1978","journal-title":"Nature"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1191\/096120301669579565","article-title":"Antinuclear antibodies: to penetrate or not to penetrate, that was the question","volume":"10","author":"Alarc\u00f3n-Segovia","year":"2001","journal-title":"Lupus"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/annrheumdis-2019-216599","article-title":"Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis","volume":"79","author":"Pinal-Fernandez","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.ard.2025.04.027","article-title":"In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis","volume":"84","author":"Giannini","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R18-20261001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13395-025-00400-7","article-title":"Complement-independent pathogenic influences of anti-HMGCR+and anti-SRP+immune-mediated necrotizing myopathy autoantibodies on engineered muscle function","volume":"16","author":"Lad","year":"2025","journal-title":"Skelet Muscle"},{"key":"R19-20261001","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ard.2025.08.023","article-title":"Myositis-specific autoantibodies recognising Mi2 also target the AIRE protein at a shared PHD zinc finger","volume":"85","author":"Musai","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1093\/rheumatology\/keaf426","article-title":"Anti-Mi2 autoantibodies target PHD fingers of SP140L and TIF1\u03b3, while anti-TIF1\u03b3 autoantibodies primarily bind TIF1\u03b3 outside the PHD region","volume":"64","author":"Pinal-Fernandez","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R21-20261001","doi-asserted-by":"crossref","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","article-title":"More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"R22-20261001","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R23-20261001","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"R24-20261001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/304177a0","article-title":"Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity","volume":"304","author":"Mathews","year":"1983","journal-title":"Nature"},{"key":"R25-20261001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0006-291X(84)91407-4","article-title":"Rat liver histidyl-tRNA synthetase. Purification and inhibition by the myositis-specific anti-Jo-1 autoantibody","volume":"120","author":"Yang","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"R26-20261001","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R27-20261001","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"19985","DOI":"10.1073\/pnas.1014074107","article-title":"Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)","volume":"107","author":"Mallery","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"R29-20261001","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1073\/pnas.0609174104","article-title":"Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function","volume":"104","author":"James","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"R30-20261001","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"R31-20261001","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"R32-20261001","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ard.2025.05.025","article-title":"OP0002 efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy: phase 2 results from the ALKIVIA study","volume":"84","author":"Chinoy","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R33-20261001","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2013 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"R34-20261001","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"key":"R35-20261001","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"R36-20261001","doi-asserted-by":"crossref","first-page":"e2217831120","DOI":"10.1073\/pnas.2217831120","article-title":"Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone","volume":"120","author":"Yogev","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"R37-20261001","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard-2022-223792","article-title":"Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis","volume":"82","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R38-20261001","doi-asserted-by":"crossref","first-page":"103375","DOI":"10.1016\/j.autrev.2023.103375","article-title":"Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature","volume":"22","author":"Guerra","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R39-20261001","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Preexisting antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R40-20261001","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1097\/RHU.0000000000001777","article-title":"Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review","volume":"28","author":"Ghosh","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"R41-20261001","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/acn3.51761","article-title":"Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis","volume":"10","author":"Masi","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"R42-20261001","doi-asserted-by":"crossref","first-page":"e2242","DOI":"10.1002\/brb3.2242","article-title":"A systematic review of myasthenia gravis complicated with myocarditis","volume":"11","author":"Cheng","year":"2021","journal-title":"Brain Behav"},{"key":"R43-20261001","doi-asserted-by":"crossref","first-page":"e1843","DOI":"10.1210\/clinem\/dgac059","article-title":"Association of antithyroid antibodies in checkpoint inhibitor-associated thyroid immune-related adverse events","volume":"107","author":"Muir","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R44-20261001","doi-asserted-by":"crossref","first-page":"e013814","DOI":"10.1136\/jitc-2025-013814","article-title":"Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma","volume":"14","author":"Reschke","year":"2026","journal-title":"J Immunother Cancer"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:02:12Z","timestamp":1790834532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001196","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}